|
BALTIMORE, MD—July 16, 2013—Med-IQ, an award-winning, ACCME-accredited provider of continuing medical education (CME), is pleased to announce the availability of its latest CME offering in colorectal cancer (CRC), Targeting Tumor Angiogenesis to Prevent the Growth of Metastatic Colorectal Cancer.
The complimentary educational series consists of two CME-certified online publications and audio commentary of expert faculty discussing key issues related to the management of patients with metastatic CRC.
“Approximately 35% of all patients diagnosed with CRC will eventually develop advanced or metastatic disease,” said John L. Marshall, MD, Director of The Ruesch Center for the Cure of GI Cancers at Georgetown University Medical Center. “The development of novel antiangiogenic agents to help slow the progression of CRC is being aggressively pursued, and the rapid pace at which oncologic therapies are being discovered can present challenges in evaluating clinical trial data and appropriately translating that evidence into practice.”
Developed for hematologists and oncologists, this complimentary CME activity explores the role of vascular endothelial growth factor in angiogenesis and reviews contemporary data regarding the efficacy and limitations of current and investigational strategies for angiogenesis inhibition in patients with metastatic CRC.
| Faculty |
| |
John L. Marshall, MD
Director, The Ruesch Center for the Cure of GI Cancers
Chief, Hematology and Oncology
Georgetown University Medical Center
Washington, DC
|
|
| |
Edith P. Mitchell, MD, FACP
Clinical Professor of Medicine and Medical Oncology
Program Leader, Gastrointestinal Oncology
Department of Medical Oncology
Associate Director of Diversity Programs
Director, Center for Elimination of Cancer Disparities
Kimmel Cancer Center at Jefferson
Thomas Jefferson University
Philadelphia, PA
|
|
This activity is approved for AMA PRA Category 1 Credit™. This activity is supported by an educational grant from Sanofi-aventis U.S. Inc., A SANOFI COMPANY, and Regeneron Pharmaceuticals.
For more information, visit www.Med-IQ.com/s45, call (toll-free) 866 858 7434, or e-mail info@med-iq.com.
|
About Med-IQ
Med-IQ, America's most respected provider of continuing medical education (CME), inspires healthcare professionals through award-winning activities that deliver sophisticated outcomes-based educational designs with measurable results in professional competence and performance. Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the California Board of Registered Nursing (CBRN), and the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing medical education to physicians, nurses, and pharmacists, respectively.
Med-IQ, a leader in the development of performance improvement (PI) and quality improvement (QI) CME initiatives, has been recognized by the Alliance for Continuing Education in the Health Professions for our excellence in CE research (William Campbell Felch Award 2013, 2011), educational collaborations (2013), outstanding CME outcomes assessment (2012), and exceptional leadership (Leadership Award 2013, President’s Award 2012). To learn more about Med-IQ, visit www.Med-IQ.com, like us on Facebook, follow us on Twitter, and connect with us on LinkedIn.
For more information, contact: |
close
